Meeting
2015 ASCO Annual Meeting
A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
Authors
Gary K. Schwartz
Columbia University Medical Center, New York, NY
Gary K. Schwartz , Douglas Adkins , Rebecca Suk Heist , Maura Abbott , Stephanie L. Barber , Richard C. Chao , Saskia T.C. Neuteboom , Isan Chen , James Christensen , Todd Michael Bauer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT02219711
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS2621)
DOI
10.1200/jco.2015.33.15_suppl.tps2621
Abstract #
TPS2621
Poster Bd #
327a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
First Author: Todd Michael Bauer
Poster
2019 ASCO Annual Meeting
A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.
First Author: Gary Edward Richardson
Poster
2024 ASCO Annual Meeting
BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.
First Author: Yufei Liu
Poster
2018 ASCO Annual Meeting
Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).
First Author: Shubham Pant